Acceleron’s Sotatercept Receives FDA’s Orphan Drug Status for PAH
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to sotatercept for the treatment of pulmonary arterial hypertension (PAH), according to…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals
Only two non-invasive diagnostic tests are required to best predict the risk of adverse events in people with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH), a new study suggests. The study, “Guideline implementation and early risk assessment in pulmonary…
Targeting Feedback Signaling Mechanism Involved in Vascular Remodeling May Prevent PH, Study Finds
Disrupting the vascular remodeling feedback signaling loop mediated by CD146-HIF-1α can effectively prevent the development of pulmonary hypertension (PH) in mice, a study found. This suggests that medicines that could target CD146-HIF-1α signals may represent a potential strategy to treat pulmonary arterial hypertension…
Interleukin-1 Receptor Antagonist Reduces PH in Newborn Mice, Study Finds
Blocking the protein interleukin-1 (IL-1) protects against pulmonary hypertension (PH) induced by complications from bronchopulmonary dysplasia (BPD) caused by high levels of oxygen, a new study in newborn mice reports. The findings have implications for the…
